Low Dose Naltrexone as it is known in the United States, or Lodonal as it is known internationally, has its origins in the FDA approved 50mg Naltrexone. Originally used to treat opiate dependences, the Immune Therapeutics patented treatments, which cover a wide range of indications, is currently used as an immune modulator.
OGF/MENK has been shown to halt the growth of the cells and is thought to allow immunological mechanisms (e.g. macrophages, natural killer cells) to accomplish the task of destroying the cancerous cells.
ORLANDO, Fla., May 19, 2016 /PRNewswire/ — Immune Therapeutics, Inc. (O
TCQB: IMUN ), a clinical-stage biotech company providing immunotherapy solutions for the treatment of infectious and non-infectious diseases, such as HIV/AIDS and cancer, with a focus on emerging nations, today announced its attendance at the 69th World Health Assembly ( ” WHA ” ) in Geneva, Switzerland to promote Lodonal™.
The WHA is the decision-making body of the World Health Organization (“WHO”). It is attended by delegations from all WHO member states and focuses on a specific health agenda prepared by the executive board. The main functions of the WHA are to determine the policies of the organization, appoint the Director-General, supervise financial policies, and review and approve the proposed programme budget (www.who.int/mediacentre/events/2016/wha69/en/).
ORLANDO, Fla., April 27, 2016 (GLOBE NEWSWIRE) — Immune Therapeutics, Inc. (OTCQB:IMUN) (the “Company”), a clinical-stage biotech company providing immunotherapy solutions for the treatment of autoimmune disease and cancer with a focus on emerging nations, today announced that Nigeria’s National Agency for Food and Drug Administration and Control (NAFDAC) has approved its patented Lodonal as an over the counter, non-toxic adjunct therapy in the treatment of HIV/AIDS and immune system regulator.
The receipt of NAFDAC’s approval will enable the Company’s distribution partner, AHAR Pharma, and GB Pharma Holdings, to launch a nationwide marketing and sales program that is expected to generate new and significant revenue channels for the Company. The Company believes that this new sales revenue places it on-track towards achieving profitability and significant future revenue and earnings growth.
NAFDAC is the Nigerian agency under the Federal Ministry of Health that is responsible for regulating and controlling the manufacture, import/export, distribution, sale and use of food and drugs. Its approval for the Company to exclusively market and distribute Lodonal in Nigeria clears the way to complete the registration over the coming weeks.
ORLANDO, FL–(Marketwired – Apr 21, 2016) – Immune Therapeutics Inc. (OTCQB: IMUN) today announced that they have signed a binding Letter of Intent to acquire Chinese Chimeric Super Antigen Receptor T cell (CAR-T) cocktail therapy, Immuno-Oncology patents (pending), manufacturing technology, and clinical data of the aforementioned therapies from Super-T Cell Cancer Company (“STCC”) a newly formed corporation.
“This CAR-T cell technology licensing further accelerates IMUN’s growth in the Immuno-Oncology field as we evaluate paths to commercialization both in China and other Emerging Markets,” commented Christopher Pearce, Chief Operating Officer.